15
Steve Holmes, PhD Director, Therapeutic Targets Kymab Limited

Steve Holmes, PhD Director, Therapeutic Targets Kymab Limited

  • Upload
    ryder

  • View
    25

  • Download
    0

Embed Size (px)

DESCRIPTION

Steve Holmes, PhD Director, Therapeutic Targets Kymab Limited. I am in the Biotechnology industry. Each gene Can be translated Into a specific protein. DNA. Proteins are large and complex and carry out the body’s functions. A code Organised into genes >30,000 in each of us. - PowerPoint PPT Presentation

Citation preview

Page 1: Steve Holmes, PhD Director, Therapeutic Targets Kymab  Limited

Steve Holmes, PhDDirector, Therapeutic Targets

Kymab Limited

Page 2: Steve Holmes, PhD Director, Therapeutic Targets Kymab  Limited

2

I am in the Biotechnology industry

DNA

A codeOrganised into genes>30,000 in each of us

Each geneCan be translated

Into a specificprotein

Proteins are large and complex

and carry out the body’sfunctions

Most biological medicinesare PROTEINS

Page 3: Steve Holmes, PhD Director, Therapeutic Targets Kymab  Limited

IgG Monoclonal AntibodyMW ca. 160,000

Biologics. Some of the Molecules

-InterferonMW ca. 18,500

Biologics : Some of the Molecules used in Medicine

Aspirin MW 180

InsulinMW ca. 6,000

Page 4: Steve Holmes, PhD Director, Therapeutic Targets Kymab  Limited

Pharmaceutical Product Sales

2000 2008 20140

10

20

30

40

50

60

70

Total Sales $Billion

• By 2014 Biologics are expected to account for 75% ($50Bn) of the revenues from the top 10 best selling drugs

• Five of the Top 10 are predicted to be monoclonal antibodies

2000 2008 20140

100

200

300

400

500

600

Biologic DrugsConventional Drugs

Top 10 - Sales $Billion

Page 5: Steve Holmes, PhD Director, Therapeutic Targets Kymab  Limited

Mechanism of Action of Monoclonal Antibodies

Monoclonal Antibody

Effector function

Unique bindingfunction

Page 6: Steve Holmes, PhD Director, Therapeutic Targets Kymab  Limited

Clinical use of Monoclonal AntibodiesRheumatoid Arthritis – Disease Reversal

Clinically Approved anti-TNFMonoclonal Antibodies for RA

RemicadeHumira

Page 7: Steve Holmes, PhD Director, Therapeutic Targets Kymab  Limited

A day in the life of Steve Holmes

►Research ideas for monoclonal antibody therapy for Amyotrophic lateral sclerosisIP, literature and competition searchesReview list of experts in field

►Prepare for meeting with Contract Manufacturing Organisation

►Attend antibody research group meeting►Attend management meeting►Telecon with Wellcome Trust►Prepare project plan for new monoclonal

Page 8: Steve Holmes, PhD Director, Therapeutic Targets Kymab  Limited

Kymab: Therapeutic monoclonal antibody company

Life cycle: idea to clinic

Ideas Research Development Late clinical trials ApprovalEarly clinical

trials

~8 years

What is my job in the cycle?• Ideas

• Research

• Development

What skills are required to do my job?• Immunology, biochemistry, molecular biology

• Antibody generation, antibody engineering, cell line development and manufacturing

• Disease biology expertise

• Clinical trials

• IP, Fund raising, Bus. Dev.

• Years of experience

• Track record

Page 9: Steve Holmes, PhD Director, Therapeutic Targets Kymab  Limited

Kymab: Therapeutic monoclonal antibody company

Life cycle: idea to clinic

Ideas Research Development Late clinical trials ApprovalEarly clinical

trials

~8 years

How did I gain the skills?What skills are required to do my job?• Immunology, biochemistry, molecular biology

• Track record

• Years of experience

• Clinical trials

• IP, Fund raising, Bus. Dev.

• Disease biology expertise

• Antibody generation, engineering, cell line development and manufacturing

Post-Doc (3 years)Assistant Professor (4 years)On job training

Page 10: Steve Holmes, PhD Director, Therapeutic Targets Kymab  Limited

Kymab: Therapeutic monoclonal antibody company

Life cycle: idea to clinic

Ideas Research Development Late clinical trials ApprovalEarly clinical

trials

~8 years

How did I gain the skills?What skills are required to do my job?• Immunology, biochemistry, molecular biology

• Track record

• Years of experience

• Clinical trials

• IP, Fund raising, Bus. Dev.

• Disease biology expertise

• Antibody generation, engineering, cell line development and manufacturing

AcademiaBiotech. and Pharma. industry

Page 11: Steve Holmes, PhD Director, Therapeutic Targets Kymab  Limited

Kymab: Therapeutic monoclonal antibody company

Life cycle: idea to clinic

Ideas Research Development Late clinical trials ApprovalEarly clinical

trials

~8 years

How did I gain the skills?What skills are required to do my job?• Immunology, biochemistry, molecular biology

• Track record

• Years of experience

• Clinical trials

• IP, Fund raising, Bus. Dev.

• Disease biology expertise

• Antibody generation, engineering, cell line development and manufacturing

AcademiaBiotech. and Pharma. industry

30+ Patents 60+ Publications

Page 12: Steve Holmes, PhD Director, Therapeutic Targets Kymab  Limited

Kymab: Therapeutic monoclonal antibody company

Life cycle: idea to clinic

Ideas Research Development Late clinical trials ApprovalEarly clinical

trials

~8 years

How did I gain the skills?What skills are required to do my job?• Immunology, biochemistry, molecular biology

• Track record

• Years of experience

• Clinical trials

• IP, Fund raising, Bus. Dev.

• Disease biology expertise

• Antibody generation, engineering, cell line development and manufacturing

Pharma and Biotech industry

Page 13: Steve Holmes, PhD Director, Therapeutic Targets Kymab  Limited

Kymab: Therapeutic monoclonal antibody company

Life cycle: idea to clinic

Ideas Research Development Late clinical trials ApprovalEarly clinical

trials

~8 years

How did I gain the skills?What skills are required to do my job?• Immunology, biochemistry, molecular biology

• Track record

• Years of experience

• Clinical trials

• IP, Fund raising, Bus. Dev.

• Disease biology expertise

• Antibody generation, engineering, cell line development and manufacturing

Biotech industry30+ Patents, 60+ publications

Page 14: Steve Holmes, PhD Director, Therapeutic Targets Kymab  Limited

Kymab: Therapeutic monoclonal antibody company

Life cycle: idea to clinic

Ideas Research Development Late clinical trials ApprovalEarly clinical

trials

~8 years

How did I gain the skills?What skills are required to do my job?• Immunology, biochemistry, molecular biology

• Track record

• Years of experience

• Clinical trials

• IP, Fund raising, Bus. Dev.

• Disease biology expertise

• Antibody generation, engineering, cell line development and manufacturing

30+ yearsMonoclonal antibodies in clinical trialsDomantis – sold to GSK for £230M

Bosatria4 mAbs

Page 15: Steve Holmes, PhD Director, Therapeutic Targets Kymab  Limited

Biotechnology Industry

Salary, Career path and career progression/promotion opportunities

BSc 0 – 4 years experience ~£18K - £35KPhD 0 – 4 years experience ~£20K - £50K

Career Path Science Career Career Opportunities

Research Associate Marketing/Sales

Scientist Patent attorney

Senior Scientist Business Dev./CBO

Director CEO

CSO Consultant

Found own company